AFYX

AFYX Therapeutics is changing the way mucosal diseases are treated. We are developing a pipeline of targeted treatments for unmet medical needs in oral health diseases, such as Head and Neck Cancer (H&N), Oral Lichen Planus (OLP) and Recurrent Aphthous Stomatitis (RAS); and women's health diseases, such as Vulvar Lichen Sclerosus (VLS)... Our Rivelin product for Vulvar Lichen Sclerosus is being evaluated in a 12-patient, open-label single-center study in Denmark. Objectives of the Phase 1 study are to obtain patient feedback on feasibility of administering patch, to evaluate adhesion time on relevant regions of the body, to understand tolerability and sensation of the Rivelin plain patch, and to address what features a Rivelin vulvar patch should encompass. Based on the study results, further work is planned to optimize the patch in terms of size, shape, active ingredients, and adhesion profile. Data is expected by early 2019... We also use different external services like Google..

Primary location: Copenhagen Denmark